Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions

References

• ICH Topic E15. Definitions of genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data, sample coding categories. 2007. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-15-definitions-genomic-biomarkers-pharmacogenomics-pharmacogenetics-genomic-data-sample-coding_en.pdf. Accessed July 10, 2019.
   Google Scholar
• Meyer Zu Schwabedissen HE. The Role of Pharmacogenomics in Individualized Medicine. Springer; 2015:93–112.
   Google Scholar
• Dunnenberger HM, Crews KR, Hoffman JM, et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol. 2015;55:89–106. doi:10.1146/annurev-pharmtox-010814-124835
   PubMed Web of Science ®Google Scholar
• Roden DM, Van Driest SL, Mosley JD, et al. Benefit of preemptive pharmacogenetic information on clinical outcome. Clin Pharmacol Ther. 2018;103:787–794. doi:10.1002/cpt.1035
   PubMed Web of Science ®Google Scholar
• Bank PCD, Swen JJ, Guchelaar HJ. Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands. BMC Med. 2019;17:110. doi:10.1186/s12916-019-1342-5
   Web of Science ®Google Scholar
• S3-Leitlinie Mammakarzinom Version 4.2; 2020. Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Mammakarzinom_4_0/Version_4.3/LL_Mammakarzinom_Kurzversion_4.2.pdf. Accessed July 15, 2020.
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–784. doi:10.1016/S0140-6736(11)60993-8
   PubMed Web of Science ®Google Scholar
• Mürdter TE, Schroth W, Bacchus-Gerybadze L, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of Phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89:708–717. doi:10.1038/clpt.2011.27
   PubMed Web of Science ®Google Scholar
• Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Therap. 2004;310:1062–1075. doi:10.1124/jpet.104.065607
   PubMed Web of Science ®Google Scholar
• Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE. PharmGKB summary: tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics. 2013;23:643–647. doi:10.1097/FPC.0b013e3283656bc1
   PubMed Web of Science ®Google Scholar
• de Vries Schultink AHM, Zwart W, Linn SC, Beijnen JH, Huitema ADR. Effects of pharmacogenetics on the pharmacokinetics and pharmacodynamics of tamoxifen. Clin Pharmacokinet. 2015;54:797–810. doi:10.1007/s40262-015-0273-3
   PubMed Web of Science ®Google Scholar
• Moon Z, Hunter MS, Moss-Morris R, Hughes LD. Factors related to the experience of menopausal symptoms in women prescribed tamoxifen. J Psychosom Obstet Gynaecol. 2017;38:226–235. doi:10.1080/0167482X.2016.1216963
   PubMed Web of Science ®Google Scholar
• Lee CI, Fox P, Balakrishnar B, et al. Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy? Breast. 2019;46:52–57. doi:10.1016/j.breast.2019.05.009
   Web of Science ®Google Scholar
• Jeiziner C, Suter K, Wernli U, et al. Pharmacogenetic information in Swiss drug labels – a systematic analysis. Pharmcogenom J. 2020.
   Google Scholar
• Tamoxifen pathway; 2020. Available from: https://www.pharmgkb.org/pathway/PA145011119. Accessed June 12, 2020.
   Google Scholar
• Dean L. Tamoxifen Therapy and CYP2D6 Genotype. Medical Genetics Summaries [Internet]: National Center for Biotechnology Information (US); 2019.
   Google Scholar
• Pharmacogenetics -recommendations and background information enzymes; 2020. Available from: https://www.knmp.nl/patientenzorg/medicatiebewaking/farmacogenetica/pharmacogenetics-1/pharmacogenetics. Accessed February 01, 2020.
   Google Scholar
• Goetz MP, Sangkuhl K, Guchelaar HJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018;103:770–777. doi:10.1002/cpt.1007
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, de Boer A, et al. Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther. 2011;89:662–673. doi:10.1038/clpt.2011.34
   PubMed Web of Science ®Google Scholar
• Rae JM, Drury S, Hayes DF, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104:452–460. doi:10.1093/jnci/djs126
   PubMed Web of Science ®Google Scholar
• Regan MM, Leyland-Jones B, Bouzyk M, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104:441–451. doi:10.1093/jnci/djs125
   PubMed Web of Science ®Google Scholar
• Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302:1429–1436. doi:10.1001/jama.2009.1420
   PubMed Web of Science ®Google Scholar
• Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28:1287–1293. doi:10.1200/JCO.2009.25.7246
   PubMed Web of Science ®Google Scholar
• Goetz MP, Suman VJ, Hoskin TL, et al. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res. 2013;19:500–507. doi:10.1158/1078-0432.CCR-12-2153
   PubMed Web of Science ®Google Scholar
• He W, Grassmann F, Eriksson M, et al. CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in patients with breast cancer. J Clin Oncol. 2020;38:548–557. doi:10.1200/JCO.19.01535
   PubMed Web of Science ®Google Scholar
• Hertz DL, Deal A, Ibrahim JG, et al. Tamoxifen dose escalation in patients with diminished CYP2D6 activity normalizes endoxifen concentrations without increasing toxicity. Oncologist. 2016;21:795–803. doi:10.1634/theoncologist.2015-0480
   PubMed Web of Science ®Google Scholar
• Vogel CL, Johnston MA, Capers C, Braccia D. Toremifene for breast cancer: a review of 20 years of data. Clin Breast Cancer. 2014;14:1–9. doi:10.1016/j.clbc.2013.10.014
   PubMed Web of Science ®Google Scholar
• Watanabe M, Watanabe N, Maruyama S, Kawashiro T. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes. Drug Metab Pharmacokinet. 2015;30:325–333. doi:10.1016/j.dmpk.2015.05.004
   Web of Science ®Google Scholar
• Kim J, Dalton JT, Veverka KA. Relationship of CYP2D6 status and toremifene metabolism. J Clin Oncol. 2011;29:e13068–e. doi:10.1200/jco.2011.29.15_suppl.e13068
   Web of Science ®Google Scholar
• Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and n-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002;30:869–874. doi:10.1124/dmd.30.8.869
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–141.
   PubMed Web of Science ®Google Scholar
• Sim S, Lövrot J, Lindh JD, Bergh J, Xie H. Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. Pharmacogenomics. 2018;19:1027–1037. doi:10.2217/pgs-2018-0089
   PubMed Web of Science ®Google Scholar
• Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25:5187–5193. doi:10.1200/JCO.2007.12.2705
   PubMed Web of Science ®Google Scholar
• Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913–958.
   PubMed Web of Science ®Google Scholar
• Weissenstein U, Kunz M, Oufir M, et al. Absence of herb-drug interactions of mistletoe with the tamoxifen metabolite (E/Z)-endoxifen and cytochrome P450 3A4/5 and 2D6 in vitro. BMC Complement Altern Med. 2019;19:23. doi:10.1186/s12906-019-2439-2
   Web of Science ®Google Scholar
• Sestak I, Kealy R, Nikoloff M, et al. Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial. Br J Cancer. 2012;107:230–233. doi:10.1038/bjc.2012.278
   PubMed Web of Science ®Google Scholar
• de Vries Schultink AHM, Huitema ADR, Beijnen JH. Therapeutic drug monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy. Breast. 2018;42:38–40. doi:10.1016/j.breast.2018.08.100
   PubMed Web of Science ®Google Scholar
• Gawronska-Szklarz B, Adamiak-Giera U, Wyska E, et al. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol. 2012;68:1267–1274. doi:10.1007/s00228-012-1252-3
   PubMed Web of Science ®Google Scholar
• Román M, Ochoa D, Sánchez-Rojas SD, et al. Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. Pharmacogenomics. 2014;15:1893–1901.
   PubMed Web of Science ®Google Scholar
• Hunfeld NG, Touw DJ, Mathot RA, et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther. 2010;31:150–159. doi:10.1111/j.1365-2036.2009.04150.x
   PubMed Web of Science ®Google Scholar
• Pace F, Pallotta S, Casalini S, Porro GB. A review of rabeprazole in the treatment of acid-related diseases. Ther Clin Risk Manag. 2007;3:363–379.
   PubMedGoogle Scholar
• Mazaleuskaya LL, Theken KN, Gong L, et al. PharmGKB summary: ibuprofen pathways. Pharmacogenet Genomics. 2015;25:96–106. doi:10.1097/FPC.0000000000000113
   PubMed Web of Science ®Google Scholar
• Katherine N, Theken CRL, Gong L, et al. CPIC guideline for NSAID and CYP2C9. 2020.
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (London, England). 2015;386:1341–1352. doi:10.1016/S0140-6736(15)61074-1
   PubMed Web of Science ®Google Scholar
• Jeong S, Woo MM, Flockhart DA, Desta Z. Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4ʹ-methanol-bisbenzonitrile in vitro. Cancer Chemother Pharmacol. 2009;64:867–875. doi:10.1007/s00280-009-0935-7
   PubMed Web of Science ®Google Scholar